Pall — Q2 2013 Earnings Presentation
21 slides from Pall's earnings presentation, Mar 1, 2013
Slide 1: Q2 FY 2013 Financial Results
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the second quarter of fiscal year 2013 are preliminary until the Company's Form 10-Q is filed with the Securities and Exchange Commission
Slide 3: Conference Call Replay Info
3 Conference Call Replay Info Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 97942344 Internet: www.pall.com/investor
Slide 4: Q2 Overview
4 Q2 Overview Life Sciences markets continue to perform well Industrial end markets are still sluggish Emerging Asia underperforming Cost saving initiatives and productivity improvements progressing FY 2013 View Generally Unchanged All remarks in this presentation are on a “Continuing Operat
Slide 5: Q2 Financial Summary
5 $640 $662 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2012 FY 2013 Q2 Financial Summary Dollars in millions, except EPS data 17.0% 17.0% 10.0% 15.0% 20.0% Operating Profit Margin FY 2012 FY 2013 Q2 FY2012 0.67$ EBIT 0.02 Translational FX (0.01) Tax Rate & Sharecount 0.05 Q2 FY2013 0.73
Slide 6: Q2 Sales by Segment
6 Life Sciences Consumables $300 +11.7% Industrial Consumables $272 -5.9% Industrial Systems $61 +21.0% Life Sciences Systems $29 Flat 41% 45% 9% 5% Q2 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts rep
Slide 7: Q2 Life Sciences Consumables
7 Q2 Life Sciences Consumables BioPharmaceuticals +11% − Strength in biotech and impact of ForteBio® Food and Beverage +5% – Geographic expansion Medical +21% – Increased Pall-Aquasafe™ sales – Increased sales to OEMs Systems Timing: Food & Beverage up; BioPharmaceuticals down Consumables
Slide 8: Q2 Life Sciences Segment Performance
8 0% 30% 60% Gross Margin Segment Margin 58.4% -100 bps 25.1% -100 bps Q2 Life Sciences Segment Performance Gross margin impacted by FX headwinds and unfavorable mix, partially offset by improved pricing Segment margin impact of cost management offset by R&D investment
Slide 9: Q2 Industrial Consumables
9 Q2 Industrial Consumables Process Technologies -12% − Weakness across end markets Aerospace +14% − Commercial aviation strength Microelectronics -6% − Continued end market weakness Systems Strength in Process Technologies and Aerospace Consumables Continued softness Commercial Aerospac
Slide 10: Q2 Industrial Segment Performance
10 0% 30% 60% Gross Margin Segment Margin 45.0% -210 bps 14.4% +30 bps Q2 Industrial Segment Performance Gross margin impacted by unfavorable mix and absorption Segment margin improvement based upon cost management
Slide 11: Q2 Regional
11 $0 $100 $200 $300 Sales Orders Sales Orders Sales Orders $209 +11.9% $211 +1.4% $265 +1.9% $188 -1.2% Americas Europe Asia $282 +8.2% $185 -7.7% Q2 Regional Dollars in millions Sales and orders changes exclude FX Sales Mature markets ~ +11% Latin America ~ +28% Orders Mature markets ~ +5%
Slide 12: Q2 Cash Flow and Working Capital
12 Q2 Cash Flow and Working Capital YTD FY13 YTD FY12 Operating Cash Flow 89$ 204$ CapEx (42) (94) Free Cash Flow 47$ 110$ Other Significant Sources/(Uses) of Cash: Pr ceeds from sale of assets 542$ 20$ Acquisition of businesses - (26) Dividends (53) (40) Borrowing/Repayment under Financing Faciliti
Slide 13: Conclusion: Closing Remarks, Q&A
13 Conclusion Closing Remarks Q&A
Slide 14: Appendix
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor
Slide 15: Q2 Earnings and FY 2013 Estimates from Continuing Operations
15 Appendix: Q2 Earnings and FY 2013 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.70$ 0.63$ 3.12$ Discrete Items: ROTC after pro forma tax effect 0.03 0.04 0.06 Tax Adjustments - - (0.09) Interest Adjustments
Slide 16: Q2 Life Sciences Sales By Market & Technology
16 Appendix: Q2 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2FY12 % Change Excluding FX Consumables Sales: BioPharmaceuticals 201,658$ (1,071)$ 202,729$ 182,518$ 11.1% Food & Beverage 45
Slide 17: Q2 Industrial Sales By Market & Technology
17 Appendix: Q2 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Consumables Sales: Process Technologies 143,146$ (899)$ 144,045$ 164,010$ -12.2% Aerospace 60,578 1
Slide 18: Q2 Sales by Segment and Region
18 Appendix: Q2 Sales by Segment and Region Reconciliation of Non-GAAP Financial Measures Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Life Sciences Sales: Americas 104,018$ (789)$ 104,807$ 84,014$ 24.8% Europe 159,360 603 158,757 152,027 4.4% As
Slide 19: Q2 Orders by Technology
19 Appendix: Q2 Orders by Technology Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q2 FY13 Q2 FY13 Estimated Impact of FX Q2 FY13 Estimate Excluding FX Q2 FY12 % Change Excluding FX Life Sciences Orders: Consumables 322,731$ (2,110)$ 324,841$ 285,748$ 13.7% Systems 28,603 175 28
Slide 20: Q2 Operating Profit
20 Appendix: Q2 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q2 FY13 Q2 FY12 Life Sciences segment profit 82,477$ 78,088$ Industrial segment profit 48,104 48,129 Total segment profit 130,581$ 126,217$ General corporate expenses (18,026) (17,678) Operating profit 11
Slide 21: Better Lives. Better Planet.
Better Lives. Better Planet.SM This presentation is the Confidential work product of Pall Corporation and no portion of this presentation may be copied, published, performed, or redistributed without the express written authority of a Pall corporate officer © 2012 Pall Corporation © 2013 Pall Corpor